

About CMOD and CAIN

CMOD is a non-profit I.R.S. 501(c)3 tax exempt organization. The mission of the International Partnership for Critical Markers of Disease (CMOD) is to accelerate the identification, validation and appropriate application of biomarkers in cardiovascular and related diseases. The broad goal of this non-profit organization is to create efficiencies toward improved patient healthcare. Toward this goal the partnership works to: 1. provide scientifically rigorous and balanced information on established and novel biomarkers and imaging technologies; 2. facilitate the cooperative exchange of ideas and information about critical biomarkers among clinical and basic scientists, governmental regulatory agencies, pharmaceutical, biotech and diagnostic companies, healthcare providers, and patient groups; 3. identify issues in biomarker identification and offer educational programs which provide access to the most current information on biomarker and related sciences to meet educational needs; and 4. promote and support collaborative initiatives to advance the identification, validation and application of biomarkers most efficiently. For more information please visit www.cmod.org.

CAIN is a pan-canadian imaging network led by Dr. Jean-Claude Tardif at the Montreal Heart Institute and funded through grants from the Canadian Foundation for Innovation (CFI) and the Canadian Institutes of Health Research (CIHR). This unique research network is focused on the pathobiology of atherosclerotic disease as it pertains to the coronary and carotid circulations. The CAIN research program involves the creation of a unique national network focused on in vivo imaging of vessel wall disease, combined with imaging of occult end-organ disease as well as the acquisition of clinical and pathological end points. CAIN will enable unprecedented cross-sectional and longitudinal clinical studies of patients with atherosclerotic disease in coronary or carotid vascular beds, and will establish an international resource for studying the natural history, progression, regression and novel therapeutic interventions aimed at atherosclerosis. Collaborations with private organizations are currently being established. For additional information, please contact jean-claude.tardif@icm-mhi.org.

Location:

828 W. Grand River Ave
Brighton, MI 48116
phone: 810.494.7193
fax: 810.494.7124

Contact:

Alita Hassan, MPH
Program Director, CMOD
ahassan@cmod.com
phone: 616.901.9814

Announcing the 1st Annual Canadian Biomarker Symposium

Sponsored by: International Partnership for Critical Markers of Disease (CMOD) and the Canadian Atherosclerosis Imaging Network (CAIN)



January 05, 2009
Novotel Hotel
Ottawa, Canada

Meeting Objectives

1. Provide the latest information on atherosclerosis imaging technologies including advantages and disadvantages, technical requirements and ongoing validation projects.
2. Identify the challenges in the development, validation and application of imaging technologies
3. Identify best practice for imaging technology assessment, validation, and application in drug development programs.
4. Review the latest imaging technology data from recently completed clinical trials.
5. Present Health Canada's perspective on imaging as a surrogate marker for atherosclerosis drug development.
6. Identify best uses of imaging technology for research, clinical practice and public health.
7. Address the potential application and hurdles associated with molecular imaging, both for cardiovascular disease, as well as other disease areas (oncology, CNS, etc).

Co-Chaired by:

Jean-Claude Tardif, M.D.

Director
Montreal Heart Institute
Research Center

Peter Libby M.D.

Chief, Cardiovascular Medicine
Brigham and Women's Hospital

2009 Faculty:

Peter Libby, M.D. - Program co-chair, Mallinckrodt Professor of Medicine
Harvard Medical School, Chief, Cardiovascular Medicine, Brigham and Women's Hospital

Jean-Claude Tardif, M.D. - Program co-chair, Director, Montreal Heart Research Centre,
Montreal Heart Institute, Professor of Medicine, University of Montreal

Robert Beanlands, M.D. - Professor of Medicine/Radiology Chief, National Cardiac PET
Centre, University of Ottawa Heart

Zahi A. Fayad, Ph.D. - Professor, Departments of Radiology and Medicine, Mount Sinai School
of Medicine

Therese Heinonen, D.V.M. - Associate Director, Medical and Scientific Affairs, Montreal Heart
Institute Coordinating Center

Dominique Johnson, Ph.D. - Director, Montreal Heart Institute Coordinating Center

Agnes Klein, M.D. - Director, Centre for the Evaluation of Radiopharmaceuticals and
Biotherapeutic Products, Health Canada

Philippe L'Allier, M.D. - Associate Director, QCA Core Laboratory, Montreal Heart Institute

Peter Liu, M.D. - Scientific Director, Institute of Circulatory and Respiratory Health, Canadian
Institutes of Health Research

Eva Lonn, M.D. - Professor of Medicine, McMaster University, Director of Echocardiography
Hamilton Health Sciences General Site

Alexander (Sandy) McEwan, M.D. FRCP (C), Chair and Professor, Department of
Oncology, Cross Cancer Institute, University of Alberta

Alan Moody, M.D. - Radiologist in Chief, Department of Diagnostic Imaging, Sunnybrook
Health Sciences Centre

Allison Mueller - Director, Regulatory Affairs, GE Healthcare

J. David Spence, M.D. - Imaging Laboratory, Robarts Research Institute

Jefferson Tea, Ph.D. - Medical Advisor, Cardiovascular, AstraZeneca Canada Inc.

David Waters, M.D. - Chief, Cardiovascular Medicine, University of California, San Francisco

Agenda:

8:00 – 8:30 am Opening Remarks

SESSION 1 Cardiovascular Focus - Atherosclerosis Imaging Technologies

8:30 - 9:00 Quantitative Coronary Angiography (QCA)

9:00 – 9:30 Intravascular Ultrasound (IVUS)

9:30 - 10:00 Carotid Ultrasound (CUS)

10:00 - 10:30 BREAK

10:30 - 11:00 Magnetic Resonance Imaging (MRI)

11:00 - 11:30 Computer Tomography (CT)

11:30 – 12:00 Positron Emission Tomography (PET)

12:00 - 1:00 LUNCH

1:00- 1:30 New Developments in Atherosclerosis Imaging Technologies

1:30 - 2:00 Cardiovascular Imaging Initiatives - CIHR

2:00 - 2:30 Biomarkers and Surrogate Endpoints in Product Development

2:30 - 3:00 Panel Discussion

3:00 - 3:30 BREAK

SESSION 2 New Frontiers in Imaging Biomarkers

3:30 - 4:00 Molecular Imaging Innovations in Cardiovascular Disease

4:00 - 4:30 Molecular Imaging Innovations in Neurovascular Disease

4:30 - 5:00 Molecular Imaging Innovations in Oncology

5:00 - 6:00 DINNER

6:00 - 6:30 Clinical Development Challenges

6:30 - 7:00 Manufacturing and Distribution Challenges

7:00 - 7:30 Regulatory Perspectives and Current Guidelines

7:30 - 8:00 Panel Discussion and Concluding Remarks

Visit www.cmod.org for
information and registration



CIHR IRSC



CAIN - Canadian Atherosclerosis Imaging Network
"Hearts and Minds"

Health
Canada

Santé
Canada

